---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Expected outcomes of therapy"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Expected outcomes of therapy. Topics: Treatment goal: continuous complete control and normal quality of life; Manufacturer statement of complete response as the treatment goal; Complete control and complete response rates in practice, CURE registry; Complete response after treatment escalation, CURE registry; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Treatment goal: continuous complete control and normal quality of life

> “The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life”
> “The overall aim of the management in urticaria is to achieve complete control of symptoms and maintain effective and safe treatment until the disease is gone.”
> “The UCT cutoff value for well-controlled disease is 12 out of 16 possible points.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.7-2"></a>

### Manufacturer statement of complete response as the treatment goal

> “Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment and achieving complete response is directly correlated to the greatest improvements in quality of life for patients.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.2.2.7-3"></a>

### Complete control and complete response rates in practice, CURE registry

> “We report real-world data from the global Chronic Urticaria Registry (CURE)”
> “At baseline, 9.8%, 17.9%, and 42.3% of patients had UCT = 16, UAS7 = 0, or PhyGA = CR, respectively, which increased at FU1 and FU2.”
> “Few patients had CR/CC of their CSU at baseline entry. Disease control strongly related to good sleep and better HRQoL; therefore, it is important to aim for CR in CSU treatment.”

Source: [Kolkhir et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36481420/)

<a id="topic-2.2.2.7-4"></a>

### Complete response after treatment escalation, CURE registry

> “This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice.”
> “Complete response was defined as UCT = 16 with a ≥ 3-point increase.”
> “After treatment escalation from BL to FU, 5.3% (no treatment to licensed-dose sgH1-AH), 6.0% (licensed-dose sgH1-AH to up-dosed sgH1-AH), and 28.4% (any dose sgH1-AH to omalizumab) achieved complete response.”
> “Appropriate treatment escalation improves CSU control, although only about a quarter of patients achieve a complete response, indicating the need for novel treatments.”

Source: [Kolkhir et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466147/)

<a id="topic-2.2.2.7-5"></a>

### Uncontrolled disease at Month 24 in antihistamine-refractory CSU, AWARE study sponsored by the manufacturer of omalizumab

> “AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.”
> “Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.”

Source: [Maurer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32735720/)

<a id="topic-2.2.2.7-6"></a>

### Real-world omalizumab complete response rate, meta-analysis supported by Novartis

> “In this meta-analysis of 67 published reports on real-world effectiveness, omalizumab therapy was associated with an average 25.6-point improvement in weekly Urticaria Activity Score (vs a 14.9 to 22.1 point improvement reported in clinical trials), a 4.7 point improvement in Urticaria Activity Score, a complete response rate of 72.2%, a partial response rate of 17.8%, and an average adverse event rate of 4.0% (vs 2.9%-8.0% reported in clinical trials).”
> “This study was supported by Novartis.”

Source: [Tharp et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439579/)

<a id="topic-2.2.2.7-7"></a>

### Barzolvolimab phase 3: complete response (UAS7=0) at Week 12

> “Celldex (NASDAQ:CLDX) today reported positive topline results from the Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.”
> “Significantly more patients achieved Complete Response (UAS7=0) with both barzolvolimab doses vs. placebo at Weeks 12 and 24.”
> “P-values are based on adjusted odds ratio of logistic regression models.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm, Week 12 | EMBARQ-CSU1 | EMBARQ-CSU2 |
| --- | --- | --- |
| Placebo | “9.3%” | “12.6%” |
| 150 mg Q4W | “42.4% (p<.00001)” | “45.7% (p<.00001)” |
| 300 mg Q8W | “42.1% (p<.00001)” | “44.0% (p<.00001)” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.2.2.7-8"></a>

### Barzolvolimab phase 2: complete response at Week 52 and at Week 76, seven months after the last dose

> “In Phase 2, the primary endpoint was met at Week 12 and patients on study continued to receive barzolvolimab for a total of 52 weeks of treatment.”
> “71% of patients treated with barzolvolimab 150 mg Q4W and 52% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 52.”
> “41% of patients treated with barzolvolimab 150 mg Q4W and 35% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 76.”
> “At Week 76, seven months after receiving their final dose of barzolvolimab, patients continued to experience profound clinical benefit on study.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
